Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Cambridge, MA 02139 Find new ideas using quick links to the Stock Screener. This generated report* has historical data on financials with interactive charts, technical indicators, and five-year peer comparison trend charts. Shares of the small-cap biopharma Seres Therapeutics Inc (NASDAQ: MCRB) were ripping higher Monday. Join us for In the Money with options strategist and CNBC contributor Dan Nathan for a weekly take on Learn everything you need to know about successful options trading with this three-part video course. Please see our, StockTwits Trending Alert: Trading recent interest in NIKOLA CORP $NKLA, StockTwits Trending Alert: Trading recent interest in ZOOM VIDEO COMMUNICATIONS INC. CLASS A COMMON STO $ZM, StockTwits Trending Alert: Trading recent interest in IMAX $IMAX, StockTwits Trending Alert: Trading recent interest in PITNEY BOWES $PBI, StockTwits Trending Alert: Trading recent interest in OWENS & MINOR $OMI. 09/10/2020. Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 11.54% and 5.16%, respectively, for the quarter ended September 2019. There may be differences between the Equity Summary Score analyst count and the number of underlying analysts listed. Learn about financial terms, types of investments, trading strategies and more. † The Equity Summary Score provided by Thomson Reuters StarMine is current as of the date specified. Seres Therapeutics, Inc., a microbiome therapeutics platform company, focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. © 2020 SwingTradeBot. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Select the link to check availability for this symbol. Further, it is developing SER-262, a multi-strain Ecobiotic microbiome therapeutic candidate, which is in Phase Ib study for CDI antibiotic treatment; and SER-155, a microbiome therapeutic candidate to correct dysbiosis in patients following allogeneic hematopoietic stem cell or solid organ transplants. Saving this view will overwrite your previously saved view. 09/22/2020, Business Wire – View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. It is also developing SER-287 that is in Phase IIb study in patients with active mild-to-moderate ulcerative colitis; and SER-401, which is in Phase Ib study in metastatic melanoma to augment the efficacy of anti-PD-1 immunotherapy. Includes articles, videos and real-time news from StockTwits. Fundamental company data provided by Morningstar and Zacks Investment Research. Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q1 2020 Results - Earnings Call Transcript. Banks Are About To Send One Of The Most Important Messages In Years. Seres Therapeutics. See what's happening in the market right now with MarketBeat's real-time news feed. View real-time stock prices and stock quotes for a full financial overview. To see all exchange delays and terms of use please see disclaimer. Filed by: FMR LLC, Company Research Highlights® Report (PDF), Industry Average & Percentile Methodology, Understanding and Using the Equity Summary Score Methodology (PDF). The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. portfolio & watchlist.